PRL and myeloid sarcoma: High levels of estrogens and progesterone are protective in women with MS (118, 119), whereas higher levels of prolactin are generally associated with increased risk of developing the disease (199–202) and clinical relapses (201, 203), even though contrasting data have been published (204, 205).